Professor James Larkin is a Consultant Medical Oncologist specialising in the treatment of patients with cancer of the kidney and cancers of the skin, including melanoma.

Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at The Institute of Cancer Research (ICR) which led to the award of a PhD. He completed specialist training at The Royal Marsden and was appointed a Consultant in 2008.

His research interests include the individualisation of patient treatment in renal cancer and melanoma, and the combination of novel targeted therapies to treat these diseases.

He is UK Chief Investigator for a number of clinical trials in melanoma and kidney cancer and has been awarded research grants from bodies including Cancer Research UK, Wellcome Trust and the European Framework Programme 7. He is a member of the NCRI Melanoma Clinical Studies Group and Chair of both the NCRI Renal Cancer Clinical Studies Group and The Royal Marsden / ICR Committee for Clinical Research.  He is currently Chair of the CRUK Clinical Research Monitoring Panel, Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at the Royal Marsden/Institute of Cancer Research Biomedical Research Centre.  In 2018 he was elected as a Fellow of the Academy of Medical Sciences.

Professor Larkin became a medical advisor to Melanoma UK in December 2013.


Dr. Aldridge is the Chair of the All Wales National Specialist Advisory Group for Skin Cancer. He has previously been the Skin Cancer MDT Lead at Cwm Taf NHS Trust for a 4-year tenure and currently operates the Rapid-Access Skin Cancer Clinic at Prince Charles Hospital, Merthyr Tydfil, which incorporates a same-day operating list which excises those skin cancers identified in clinic without delay.

Dr. Aldridge is a graduate of the University of Cardiff, School of Medicine where he obtained a BSc Hons in Physiology and graduated from Medical school in 1998. He specialised in Dermatology and has developed a sub-speciality interest in Skin Cancer; in particular, the management of Melanoma. He is a member of the British Association of Dermatologists, the British Society of Dermatological Surgery and the American Academy of Dermatology.

Dr. Aldridge has had research published in respected peer-reviewed journals and his ongoing clinical activities involve the development of a Teledermatology service, which aids triaging of suspect lesions from GPs via photo/email service. There are also close links with allied colleagues in oncology and plastic surgery in order to provide an exemplary service for the total treatment of Melanoma, for patients within his Trust.

Equally important to Dr. Aldridge is the need to raise awareness of Skin Cancer as timely intervention makes a huge difference. This is undertaken using different approaches for e.g from talks and meetings to local GPs to using social networking sites for e.g Twitter, to propagate the salient points and to keep the public abreast of recent developments.

Dr Aldridge became a medical advisor to Melanoma UK in November 2013.


MD, MB, ChB, FRCP (London)

Professor Wagstaff trained as a Medical Oncologist at the Christie Hospital in Manchester. On completion of his training he took up a position as a Senior Lecturer at the Free University Hospital in Amsterdam in 1986. In 1994 he was appointed as the Karl Landsteiner Professor of Medical Oncology at the Free University. In 1998 he became Professor & Head of Haematology and Oncology at the University of Maastricht in the Netherlands.

Dr Wagstaff is currently Professor of Medical Oncology within the College of Medicine at Swansea University. He is also Director of the Wales Cancer Research Network and Deputy Director of the Wales National Institute for Social Care and Health Research Clinical research Centre (NISCHR-CRC).

He is a member of the European Society of Medical Oncology, American Society for Clinical Oncology, Association of Cancer Physicians UK, UK National Cancer Research institute’s melanoma and renal cancer clinical study Groups and the European Organisation for Research and Treatment of Cancer.

Professor Wagstaff has co-authored over 127 papers in International Peer reviewed journals. His main research interests are renal cancers, melanoma and sarcomas. He is interested in immunotherapy and the interaction between the immune system and the neo-vasculature within tumours. His main focus has been in developing clinical trials for patients with the above diseases and conducting translational research to better understand the effects of new treatments on patients with cancer.


Professor J Meirion Thomas is Melanoma UK’s Senior Surgeon and has extensive knowledge of melanoma.

He has been a Senior Surgeon on the Sarcoma and Melanoma Unit at the Royal Marsden Hospital for 29 years.  He has a track record in clinical management and research in the treatment of melanoma.

Meirion’s research subjects encompass almost the whole breadth of melanoma but he has written extensively on the subject of sentinel node biopsy, pointing out that its benefits have been exaggerated and over-stated.


Sandra Phinbow (Nee Richards) is an experienced chartered specialist biomedical scientist, having also worked as a diagnostic dermatology manager.

She is a National Council Member for the Institute of Biomedical Science and leads on public engagement. Sandra has won several awards for her work in the public engagement of science including the Top 100 Leading Scientists in the UK list, all culminating into her entry to Who's Who in 2014.


Dr Nicole Chiang is a Consultant Dermatologist on the GMC Specialist Register who works in the NHS in Manchester. She is trained in both paediatric and adult dermatology. She completed her undergraduate studies at the University of Liverpool and graduated with an Honours degree in Medicine and Surgery in 2007. She underwent general medical training and then pursued her dermatology higher specialist training in Birmingham and Manchester.

She has completed two advanced Dermatology Fellowships in Oxford, UK and Sydney, Australia. In addition, she has gained further experience in medical and cosmetic dermatology at the Brigham and Women’s Hospital, Boston, and the Cosmetic Surgery and Skin Health Centre, Pittsburgh, USA.


Mr. Myles Smith is a Consultant Surgical Oncologist and General Surgeon in the Sarcoma Unit and Skin Unit at The Royal Marsden since 2014. Prior to appointment at the Royal Marsden he trained as General Surgeon in Ireland and subsequently underwent additive specialist training in General Surgical Oncology, as a fellow at the University of Toronto.

He has a special interest in surgery for melanoma, in particular surgical treatment of oligometastatic disease, use of regional therapies for melanoma metastasis such as T-VEC, and the management of anorectal and visceral melanoma. He is honorary faculty member of the Institute of Cancer Research, and one of his research interests is in investigating biomarkers for lymph node metastasis in melanoma.   

Myles joined Melanoma UK as an advisor in 2018.